Caris FOLFIRSTai is the first clinically validated, AI-powered molecular predictor of chemotherapy efficacy for mCRC patients. Caris FOLFIRSTai is included for mCRC cases at no additional cost, increased turnaround time or added specimen requirements.

Navigate mCRC Standard-of-Care Chemotherapy with Caris FOLFIRSTai

Traditionally, FOLFOX or FOLFIRI chemotherapy (in combination with bevacizumab) are considered for firstline metastatic colorectal cancer (mCRC) treatment, when patients are unable to tolerate FOLFOXIRI. Now oncologists have an Artificial Intelligence (AI)-based predictor intended to gauge a mCRC patient’s likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV versus FOLFIRI+BV followed by FOLFOX+BV treatment.

Caris FOLFIRSTai Validation Data

Using two independent data sets (real-world evidence and Phase III TRIBE2 study data), FOLFIRSTai demonstrated that the overall survival (OS) of patients treated in a manner consistent with the FOLFIRSTai prediction was 17.5 months longer (71%) than the OS of patients treated counter to the prediction.1
  • 412 cases were manually curated cases with real-world evidence (RWE), which includes data acquired from insurance claims records, electronic medical records and death registries.
  • 149 cases analyzed retrospectively from the randomized, prospective phase III TRIBE2 study.
Median Overall Survival Caris FOLFIRSTai Indicates:
(FOLFOX+BV RWE cohort)
OS When Patient Received:
(Figure A)
42.0 Months 18.7 Months
OS When Patient Received:
(Figure B)
24.5 Months 34.4 Months
1. Abraham JP, Magee D, Cremolini C, Antoniotti C, Halbert DD, Xiu J, Stafford P, Berry DA, Oberley MJ, Shields AF, Marshall JL, Salem ME, Falcone A, Grothey A, Hall MJ, Venook AP, Lenz HJ, Helmstetter A, Korn WM, Spetzler DB. Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer. Clin Cancer Res. 2020 Dec 8:clincanres.3286.2020. doi:10.1158/1078-0432.CCR-20-3286. Epub ahead of print. PMID: 33293373.

How it Works

Comprehensive tumor profiling is performed – FOLFIRSTai is included in Caris mCRC orders. State-of-the-art AI is applied to the molecular testing results to identify a unique molecular signature that predicts a mCRC patient’s likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV, or FOLFIRI+BV followed by FOLFOX+BV treatment.

  mCRC Patients Eligible for First-Line FOLFOX or FOLFIRI Treatment  
  Caris FOLFIRSTai Logo | Caris Life Sciences  
  MI FOLFOXai Logo | Caris Life Sciences  
Consider FOLFOX+BV First,
Followed by FOLFIRI+BV
Consider FOLFIRI+BV First,
Followed by FOLFOX+BV

Example Caris Report: Caris FOLFIRSTai Result

Caris FOLFIRSTai Example Report

For illustrative purposes only, not for clinical use. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all available information concerning the patient’s condition.

Not available in New York state.

Complete the form below to get in contact with your local representative